アドセトリスの世界市場レポート 2025年：疫学、パイプライン分析、市場インサイトと予測

アドセトリス市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9％で19億5,470万米ドルに成長します。予測期間の成長は、腫瘍学研究への投資の増加、精密医療への需要の高まり、新興市場への拡大、患者アクセスプログラムへの注目の高まり、適応拡大のための進行中の臨床検査などに起因すると考えられます。予測期間における主要動向としては、がん領域における標的療法の採用拡大、CD30陽性悪性腫瘍の新規適応拡大、新興市場におけるヘルスケア支出とアクセスの増加、抗体薬剤複合体技術の進歩、個別化がん治療に対する需要の増加などが挙げられます。

がんの有病率の増加は、今後数年間におけるアドセトリス市場の成長を牽引すると予測されます。がんは、体内の異常細胞の制御不能な増殖と拡散を特徴とする疾患の集合体です。がん患者の増加は、食生活の乱れや運動不足などのライフスタイル要因、環境汚染物質への曝露の増加、診断方法の進歩などが主要原因となっています。アドセトリスは、CD30陽性のがん細胞を特異的に標的として結合し、強力な細胞傷害性薬剤を腫瘍に直接送達し、治療効果を改善し、全身的な副作用を最小限に抑え、ある種のホジキンリンパ腫や他のCD30発現がんの患者に有望な治療選択肢を提示することにより、がん患者に大きな利益をもたらします。例えば、2023年1月、米国がん協会は、米国におけるがん罹患者数が195万8,310人に達し、がん関連死が60万9,820人に達したと報告しました。その結果、がん罹患率の増加がアドセトリス市場を牽引する重要な要因となっています。

アドセトリス市場の顕著な動向は、強化された抗体薬剤複合体（ADC）の開発や、併用療法を含むドラッグデリバリーシステムの改良に焦点が当てられていることです。これらの戦略は、治療効果を向上させ、副作用を最小限に抑え、がん細胞をより正確に標的とすることを目的としています。併用療法は、作用機序の異なる2種類以上の治療を、多くの場合相乗的に使用することで、有効性を高め、耐性を低下させ、患者の転帰を向上させるものであり、同時に単剤療法に比べて副作用を低下させる可能性があります。例えば、2023年10月、武田薬品工業は、前治療歴のないCD30+ステージIIIホジキンリンパ腫の成人患者を対象に、アドセトリス（ブレンツキシマブ・ベドチン）とドキソルビシン、ビンブラスチン、ダカルバジン（AVD）との併用療法について、欧州委員会（EC）から承認を取得しました。このADCは、ホジキンリンパ腫の重要なマーカーであるCD30を標的とします。本検査の結果、アドセトリスとAVDを併用することにより、標準治療と比較して無増悪生存期間と全生存期間が有意に改善することが示されました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のアドセトリス：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のアドセトリス市場：成長率分析
• 世界のアドセトリス市場の実績：規模と成長、2019～2024年
• 世界のアドセトリス市場の予測：規模と成長、2024～2029年、2034年
• 世界のアドセトリス：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のアドセトリス市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 粉末
• 液体
• 世界のアドセトリス市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• ホジキンリンパ腫
• 全身性未分化大細胞リンパ腫
• 皮膚T細胞リンパ腫
• その他
• 世界のアドセトリス市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• ドラッグストア
• その他

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のアドセトリス市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のアドセトリス市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• アドセトリス市場：競合情勢
• アドセトリス市場：企業プロファイル
  • Takeda Pharmaceutical Company Limited
  • Seagen Inc.

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• アドセトリス市場、2029年：新たな機会を提供する国
• アドセトリス市場、2029年：新たな機会を提供するセグメント
• アドセトリス市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) designed to target CD30, a protein present on the surface of certain cancer cells, including those associated with Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It combines a monoclonal antibody with a cytotoxic agent, monomethyl auristatin E (MMAE), enabling targeted chemotherapy delivery to cancer cells, enhancing efficacy while minimizing off-target side effects.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary forms of adcetris are powder and liquid. It is provided as a sterile, white to off-white lyophilized powder in single-dose vials. Before administration, healthcare providers reconstitute the powder with a specified amount of sterile water to prepare it for intravenous infusion. Its indications include Hodgkin lymphoma, systemic anaplastic large-cell lymphoma, cutaneous T-cell lymphoma, and others. Adcetris is utilized in various settings, such as hospitals, drug stores, and more.

The adcetris market research report is one of a series of new reports from The Business Research Company that provides adcetris market statistics, including adcetris industry global market size, regional shares, competitors with a adcetris market share, detailed adcetris market segments, market trends, and opportunities, and any further data you may need to thrive in the adcetris industry. This adcetris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adcetris market size is expected to see strong growth in the next few years. It will grow to $1,954.7 million in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to rising investment in oncology research, increasing demand for precision medicine, expansion into emerging markets, growing focus on patient access programs, ongoing clinical trials for expanded indications. Major trends in the forecast period include increasing adoption of targeted therapies in oncology, expansion into new indications for CD30-positive malignancies, growth in healthcare spending and access in emerging markets, advancements in antibody-drug conjugate technologies, increasing demand for personalized cancer treatments.

The increasing prevalence of cancer is projected to drive the growth of the adcetris market in the coming years. Cancer is a collection of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The rise in cancer cases is largely attributed to lifestyle factors, such as poor diet and physical inactivity, increased exposure to environmental pollutants, and advancements in diagnostic methods. Adcetris provides substantial benefits for cancer patients by specifically targeting and binding to CD30-positive cancer cells, delivering potent cytotoxic agents directly to the tumor, improving treatment effectiveness, minimizing systemic side effects, and presenting a promising treatment option for patients with certain types of Hodgkin lymphoma and other CD30-expressing cancers. For example, in January 2023, the American Cancer Society reported that the number of cancer cases in the United States reached 1,958,310, with 609,820 cancer-related deaths. As a result, the growing incidence of cancer is a key factor driving the adcetris market.

A prominent trend in the adcetris market is the focus on developing enhanced antibody-drug conjugates (ADCs) and improved drug delivery systems, including combination therapies. These strategies aim to improve therapeutic efficacy, minimize side effects, and more precisely target cancer cells. Combination therapies involve using two or more therapeutic agents with different mechanisms of action, often in synergy, to boost efficacy, reduce resistance, and enhance patient outcomes, while potentially lowering adverse effects compared to monotherapy. For instance, in October 2023, Takeda Pharmaceutical Company received approval from the European Commission (EC) for the use of ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for treating adults with previously untreated CD30+ Stage III Hodgkin lymphoma. This ADC targets CD30, a key marker in Hodgkin lymphoma. The trial results showed that combining ADCETRIS with AVD significantly improved both modified progression-free survival and overall survival rates compared to standard treatments.

In January 2024, Pfizer Inc. acquired Seagen Inc. for $43 billion. This acquisition aims to strengthen Pfizer's oncology portfolio by incorporating Seagen's innovative ADCs, including Adcetris, to enhance its cancer treatment offerings. The move is designed to drive growth in targeted therapies and accelerate Pfizer's ability to deliver advanced cancer treatments to patients worldwide. Seagen Inc. is a US-based biotechnology firm that markets Adcetris.

Major players operating in the adcetris market are Takeda Pharmaceutical Company Limited; Seagen Inc.

North America was the largest region in the adcetris market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in adcetris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the adcetris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adcetris market consists of sales of brentuximab vedotin-based therapies such as antibody-drug conjugates (ADCs), bispecific antibodies, and immune checkpoint inhibitors for the treatment of lymphoma and related cancers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adcetris Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adcetris market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adcetris ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adcetris market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Powder; Liquid
• 2) By Indication: Hodgkin Lymphoma; Systemic Anaplastic Large Cell Lymphoma; Cutaneous T-Cell Lymphoma; Other Indication
• 3) By Application: Hospital; Drugs Store; Other Applications
• Companies Mentioned: Takeda Pharmaceutical Company Limited; Seagen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Adcetris Market Characteristics

3. Adcetris Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Adcetris Market Trends And Strategies

5. Adcetris Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Adcetris Growth Analysis And Strategic Analysis Framework

• 6.1. Global Adcetris PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Adcetris Market Growth Rate Analysis
• 6.4. Global Adcetris Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Adcetris Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Adcetris Total Addressable Market (TAM)

7. Global Adcetris Market Pricing Analysis & Forecasts

8. Adcetris Market Segmentation

• 8.1. Global Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Podwer
• Liquid
• 8.2. Global Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hodgkin Lymphoma
• Systemic Anaplastic Large Cell Lymphoma
• Cutaneous T-Cell Lymphoma
• Other Indication
• 8.3. Global Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Drugs Store
• Other Applications

9. Global Adcetris Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Adcetris Market Regional And Country Analysis

• 10.1. Global Adcetris Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Adcetris Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Adcetris Market

• 11.1. Asia-Pacific Adcetris Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Adcetris Market

• 12.1. China Adcetris Market Overview
• 12.2. China Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Adcetris Market

• 13.1. India Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Adcetris Market

• 14.1. Japan Adcetris Market Overview
• 14.2. Japan Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Adcetris Market

• 15.1. Australia Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Adcetris Market

• 16.1. South Korea Adcetris Market Overview
• 16.2. South Korea Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Adcetris Market

• 17.1. Western Europe Adcetris Market Overview
• 17.2. Western Europe Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Adcetris Market

• 18.1. UK Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Adcetris Market

• 19.1. Germany Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Adcetris Market

• 20.1. France Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Adcetris Market

• 21.1. Eastern Europe Adcetris Market Overview
• 21.2. Eastern Europe Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Adcetris Market

• 22.1. North America Adcetris Market Overview
• 22.2. North America Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Adcetris Market

• 23.1. USA Adcetris Market Overview
• 23.2. USA Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Adcetris Market

• 24.1. Canada Adcetris Market Overview
• 24.2. Canada Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Adcetris Market

• 25.1. South America Adcetris Market Overview
• 25.2. South America Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Adcetris Market

• 26.1. Middle East Adcetris Market Overview
• 26.2. Middle East Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Adcetris Market

• 27.1. Africa Adcetris Market Overview
• 27.2. Africa Adcetris Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Adcetris Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Adcetris Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Adcetris Market Competitive Landscape And Company Profiles

• 28.1. Adcetris Market Competitive Landscape
• 28.2. Adcetris Market Company Profiles
  • 28.2.1. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. Seagen Inc. Overview, Products and Services, Strategy and Financial Analysis

29. Global Adcetris Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Adcetris Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Adcetris Market

32. Recent Developments In The Adcetris Market

33. Adcetris Market High Potential Countries, Segments and Strategies

• 33.1 Adcetris Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Adcetris Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Adcetris Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer